BCRF

When Suncera Johnson was diagnosed with breast cancer, research changed the course of her care—and her life. “Supporting the Breast Cancer Research Foundation means that people like me can have better quality of cancer care.” From genetic testing to personalized treatment decisions, research helped ensure Suncera received the care she needed and deserved. Every patient should have access to the same standard of care. #breastcancer #bcrf #researchisthereason

Breast cancer survival shouldn’t be dictated by race, income, or zip code. BCRF investigator Dr. Lisa Newman explains how BCRF investigators are confronting disparities through research into biology, genetics, access, environment, and social determinants of health. This is what real health equity looks like. #breastcancer #bcrf #equity #healthequity #disparities

We spoke with Dr. Sara Tolaney, BCRF investigator and 2025 AACR Outstanding Investigator Award for Breast Cancer Research recipient, at #SABCS25 to unpack key research advances from the conference. Here, she breaks down new insights from the landmark TAILORx study and how recurrence scores, along with emerging AI-driven tools, may help identify which patients with node-negative, hormone receptor–positive breast cancer truly benefit from chemotherapy. This research is helping spare patients unnecessary treatment while more accurately predicting risk—a shift that could transform care in the U.S. and around the world. #breastcancer #bcrf #chemotherapy #ai

Building healthier habits during and after breast cancer treatment can feel overwhelming—but it doesn’t have to be. BCRF investigator Dr. Neil Iyengar encourages starting small, assessing where you are, and identifying areas you feel motivated to improve, whether it’s nutrition, exercise, or social connections. #breastcancer #bcrf #healthy #lifestyle

There’s a lot of misinformation about diet and cancer. BCRF investigator Dr. Neil Iyengar explains: no single food can cure or prevent cancer, but a plant-forward, minimally processed diet may help reduce side effects and support better outcomes after a diagnosis. #breastcancer #bcrf #diet #lifestyle #risk

We spoke with Dr. Sara Tolaney, BCRF investigator and 2025 AACR Outstanding Investigator Award for Breast Cancer Research recipient, at #SABCS25 to unpack a key theme from the conference: the essential role of patient advocacy in advancing research. Throughout the meeting, patient advocates shared their lived experiences, helped shape conversations around emerging data, and ensured research stays grounded in what matters most to patients. As Dr. Tolaney explains, advocates are routinely involved in reviewing and providing feedback on clinical trial design—keeping the patient voice at the center of every step of the research process. #breastcancer #bcrf #breastcancerresearchfoundation

Exercise plays an important role in overall health and can help lower breast cancer risk, but it’s important to be clear: exercise cannot prevent breast cancer on its own. To kick off the new year, BCRF investigator Dr. Neil Iyengar shares how research shows regular physical activity may reduce breast and other cancer risk, improve outcomes after a diagnosis, support long-term health, and potentially lower the risk of recurrence. #breastcancer #exercise #bcrf #breastcancerresearchfoundation #lifestyle

We met with BCRF investigator Dr. Neil Iyengar to share key insights from #ESMO25, an annual meeting in Europe dedicated to advancing cancer research and treatment. Dr. Iyengar discusses the emerging research around a hot topic in the world of wellness: GLP-1 medications—and the potential role they may play in cancer treatment and risk reduction. #breastcancer #breastcancerawareness #glp1s #esmo

We spoke with Dr. Sara Tolaney, BCRF investigator and 2025 AACR Outstanding Investigator Award for Breast Cancer Research recipient, at #SABCS25 to unpack key research advances from the conference. Here, she breaks down promising updates on oral SERDs for metastatic hormone receptor–positive breast cancer, including FDA-approved Imlunestrant for ESR1-mutant disease, and emerging evidence that oral SERDs—alone or in combination—may help patients live longer while effectively controlling their cancer. These advances offer meaningful hope for patients and families navigating metastatic breast cancer. #breastcancer #breastcancerawareness #metastaticbreastcancer

We met with BCRF investigator Dr. Neil Iyengar to discuss key findings from #ESMO25, an annual meeting in Europe dedicated to advancing cancer research and treatment. Dr. Iyengar explores new insights into young-onset breast cancer—from emerging risk factors to how research is shaping earlier detection and personalized treatment for younger patients. #bcrf #breastcancerawareness #breastcancer

Breaking news from #SABCS25: Results from the decade-long WISDOM trial are reshaping what we know about breast cancer screening. Researchers compared annual mammography to a personalized, risk-based approach—using comprehensive risk assessment, including genetic testing, to guide when to start, how often to screen, and who may benefit most from prevention strategies. According to BCRF investigator Dr. Laura Esserman, this tailored model aims to ensure women receive screening at the frequency and age that is right for them. Study authors estimate that this model could help save 4,000-5,000 lives each year. The WISDOM Study 2.0 is now open to the public. Stay tuned for more.

We’re at SABCS with Dr. Gaorav Gupta, who is offering new insight into a question that has long evaded answers: Can immunotherapy be effective in hormone receptor-positive (HR+) breast cancer? Immunotherapy has had some success in triple-negative breast cancer, but not as much in other subtypes. Dr. Gupta’s study tested whether delivering focused radiation w/pembro prior to surgery could create an immune-stimulating signal that makes immunotherapy more effective for HR+/HER2- breast cancers. Early findings show this approach is safe, biologically active, and could represent a new treatment paradigm worth exploring in future trials. More updates from #SABCS25 coming soon.

A major update from #SABCS25: BCRF investigator Dr. Aditya Bardia shares encouraging results from the lidERA trial, studying a new hormone therapy called giredestrant for early HR+ breast cancer. In the trial, giredestrant lowered the risk of cancer coming back and showed fewer treatment-related side effects, meaning it may be both more effective and easier to stay on than current options. If approved, it could become the first new adjuvant endocrine therapy in decades. FDA review is expected in 2026. Here he answers some critical questions, including its potential use in combination with other drugs and for other types of breast cancer.

Confused by all the new treatment terms? You’re not alone. In this breakdown, @Eleonora Teplinsky, MD walks through three key classes of medications used in hormone receptor–positive breast cancer: aromatase inhibitors (AIs), CDK4/6 inhibitors, and SERDs. These options play different roles in treatment today and new data is helping us understand how they may help patients in the future. Stay tuned for more from #SABCS25 coming soon!

Live from SABCS, the world’s largest breast cancer conference, we’re joined by patient advocate @Annie Bond | MBC at 26 to share the metastatic breast cancer perspective and what she’s most looking forward to this year. ✨ BCRF-funded investigators have patients at the center of every research study, keeping quality of life balanced with treatment efficacy at the heart of their work. Stay tuned for more coverage and key takeaways from #SABCS25 coming soon! *Editor’s Note: SABCS began in 1978, while the first advocate program officially launched nearly 28 years ago in 1997.